Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 in Patients After Allogeneic Stem Cell Transplantation
NCT03023631Phase 4Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2017
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2017; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03023631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03023631.